|
Phosphagenics has focused its pharmaceutical research efforts towards maximizing the development of its patented transdermal delivery technology TPM. As a result of recent significant successes in this area, and initial in-vitro research, it is now planned to expand this development by exploring the application of our platform in delivering drugs both orally and via the pulmonary route.
The potential benefits of transdermal drug delivery have been widely reported in scientific literature and include a reduction in dose related side effects, the prevention of first-pass hepatic elimination and gastrointestinal degradation, as well as improved patient compliance.
Phosphagenics currently has two pharmaceutical grade transdermal delivery systems under development:
· TPM-01, for delivery of small molecules
· TPM-02, for delivery of both small and large molecules (e.g. peptides)
The key distinguishing features that contribute to the uniqueness and advantages of both these delivery systems, and the benefits they provide with respect to transdermal delivery are summarised below.
|